Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$124.31

-2.99 (-2.35%)

, CLVS

Clovis

$75.60

-1.69 (-2.19%)

07:19
08/09/17
08/09
07:19
08/09/17
07:19

Tesaro Zejula off to 'strong initial launch, says Leerink

Leerink analyst Seamus Fernandez notes that Tesaro (TSRO) reported Q2 earnings with $25.9M in Zejula sales during its first quarter on the market following approval for second-line or greater ovarian cancer maintenance, more than doubling consensus estimates. With more than 1,500 new patient starts in the quarter, Zejula is off to a "strong" initial launch, he adds. However, the analyst believes it will likely soon face competition from Clovis' (CLVS) Rubraca and AstraZeneca's (AZN) Lynparza following their likely approvals in this setting. Fernandez reiterates a Market Perform rating and $143 price target on Tesaro's shares.

TSRO

Tesaro

$124.31

-2.99 (-2.35%)

CLVS

Clovis

$75.60

-1.69 (-2.19%)

AZN

AstraZeneca

$29.30

-0.32 (-1.08%)

TSRO Tesaro
$124.31

-2.99 (-2.35%)

08/08/17
MSCO
08/08/17
NO CHANGE
MSCO
Morgan Stanley buyers of Clovis and Tesaro into Lynparza label decision
Morgan Stanley analyst Andrew Berens would be a buyer of Clovis (CLVS) and Tesaro (TSRO) ahead of the broad label decision for AstraZeneca's (AZN) Lynparza in 2L maintenance setting expected in Q3. Berens sees minimal fundamental impact to both stocks, even if AstraZeneca receives a broad label. He thinks a broad label will be limited to BRCA patients, or the FDA will place caveats as having inferior data outside of BRCA, and both stocks will benefit as an overhang is lifted.
08/01/17
JANY
08/01/17
NO CHANGE
JANY
Neutral
Robust launch for Idhifa already reflected in Agios shares, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said he anticipates rapid adoption of Idhifa and expects a robust commercial launch led by Agios' (AGIO) partner Celgene (CELG), but he also believes this is reflected in the stock. The wholesale acquisition cost of $24,872 is significantly higher than Tesaro's (TSRO) Zejula and Clovis' (CLVS) Rubraca, noted Chattopadhyay, who added that the higher WAC and potentially longer median duration of therapy represents upside to his current estimates. He keeps a Neutral rating on Agios, which will receive a low double digit to mid teens royalty for Idhifa.
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
CLVS Clovis
$75.60

-1.69 (-2.19%)

07/31/17
JPMS
07/31/17
NO CHANGE
JPMS
Clovis takeover thesis not off the table, says JPMorgan
JPMorgan said the Clovis (CLVS) and Bristol-Myers (BMY) collaboration does not impact the takeover thesis of Clovis. Analyst Cory Kasimov said the the no-strings-attached clinical collaboration has no financial terms aside from provision of study drug and sharing of trial costs in some instances and Bristol does not have first rights of refusal if an interested party did approach Clovis.
07/31/17
LEER
07/31/17
NO CHANGE
LEER
Outperform
Clovis weakness unwarranted after Bristol-Myers pact, says Leerink
Leerink analyst Michael Schmidt thinks today's weakness in Clovis (CLVS) is unwarranted following the company's clinical collaboration agreement with Bristol-Myers (BMY) and presents a buying opportunity. This deal does not preclude a future acquisition of the company, but it does increase the competitiveness and value of Rubraca, argues Schmidt, who reiterates his Outperform rating on Clovis shares.
AZN AstraZeneca
$29.30

-0.32 (-1.08%)

08/09/17
PIPR
08/09/17
NO CHANGE
PIPR
Overweight
AstraZeneca recent selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss believes the recent negative MYSTIC update from AstraZeneca has created a long-term buying opportunity. 2017 marks an earnings trough year for the company, and the shares now trade at discounted valuation, Purkiss tells investors in a research note. He reiterates an Overweight rating on the shares with a GBP 51 price target.
08/01/17
PART
08/01/17
UPGRADE
PART
Hold
AstraZeneca upgraded to Hold from Sell at Pareto
07/28/17
07/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) was downgraded to Neutral from Buy at Guggenheim and to Hold from Buy at Stifel. 2. Spirit Airlines (SAVE) was downgraded to Neutral from Buy at Buckingham and BofA/Merrill and to In-Line from Outperform at Imperial Capital. 3. Flowers Foods (FLO) downgraded to Hold from Buy at Jefferies with analyst Akshay Jagdale saying his positive thesis on bread industry pricing becoming more rational has not played out. 4. AstraZeneca (AZN) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Vincent Meunier saying shares look fairly valued as he removed MYSTIC from his models. 5. U.S. Steel (X) downgraded to Sell from Neutral at Citi with analyst Alexander Hacking saying he sees downside risk to U.S. flat rolled prices for the remainder of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SPN

Superior Energy

$8.81

-0.14 (-1.56%)

21:18
11/20/17
11/20
21:18
11/20/17
21:18
Upgrade
Superior Energy rating change  »

Superior Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$78.90

-0.59 (-0.74%)

, LOW

Lowe's

$81.46

1.24 (1.55%)

20:25
11/20/17
11/20
20:25
11/20/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$78.90

-0.59 (-0.74%)

LOW

Lowe's

$81.46

1.24 (1.55%)

ADI

Analog Devices

$93.07

2.65 (2.93%)

DLTR

Dollar Tree

$97.11

2.5 (2.64%)

HRL

Hormel Foods

$33.40

0.28 (0.85%)

CPB

Campbell Soup

$49.93

0.21 (0.42%)

BURL

Burlington Stores

$106.55

1.82 (1.74%)

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

DSW

DSW

$22.53

0.38 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 01

    Dec

  • 07

    Dec

  • 08

    Dec

  • 09

    Jan

CCLP

CSI Compressco

$5.28

-0.16 (-2.94%)

19:32
11/20/17
11/20
19:32
11/20/17
19:32
Hot Stocks
CSI Compressco names Owen Serjeant president »

CSI Compressco announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$57.62

1.13 (2.00%)

, AAPL

Apple

$169.98

-0.17 (-0.10%)

19:04
11/20/17
11/20
19:04
11/20/17
19:04
Periodicals
Applied Materials expected to purchase former Apple complex, Mercury News says »

An office complex that…

AMAT

Applied Materials

$57.62

1.13 (2.00%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

, FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

18:21
11/20/17
11/20
18:21
11/20/17
18:21
Periodicals
Fox reaches $90M settlement over sexual harassment scandal, Reuters says »

21st Century Fox reached…

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$188.00

2.87 (1.55%)

18:19
11/20/17
11/20
18:19
11/20/17
18:19
Hot Stocks
Muddy Waters says Alibaba numbers 'obviously fake' »

Short seller Muddy Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

, CHKP

Check Point

$102.98

0.83 (0.81%)

18:15
11/20/17
11/20
18:15
11/20/17
18:15
Recommendations
Palo Alto Networks, Check Point, Fortinet analyst commentary at JPMorgan »

Palo Alto quarter…

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

CHKP

Check Point

$102.98

0.83 (0.81%)

FTNT

Fortinet

$40.77

0.46 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 07

    Dec

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

18:14
11/20/17
11/20
18:14
11/20/17
18:14
Hot Stocks
Amazon announces cloud software for U.S spy agencies AWS Secret Region »

Amazon announced the new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

, RHHBY

Roche

$30.82

1.72 (5.91%)

18:08
11/20/17
11/20
18:08
11/20/17
18:08
Recommendations
Deutsche cuts Bioverativ target to $53 after positive Roche data »

Deutsche Bank analyst…

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

RHHBY

Roche

$30.82

1.72 (5.91%)

SHPG

Shire

$141.37

-6 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Dec

  • 23

    Dec

  • 23

    Feb

CUBI

Customers Bancorp

$27.04

0.28 (1.05%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
Customers Bancorp: Flagship could raise capital in IPO transaction in 1H18 »

Customers Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
AT&T CEO says has offered DOJ solutions that were not accepted »

Says DOJ suit throws lots…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NGD

New Gold

$3.21

-0.02 (-0.62%)

18:02
11/20/17
11/20
18:02
11/20/17
18:02
Hot Stocks
New Gold announces sale of Peak Mines for $58M »

New Gold announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMI

Intermolecular

$1.31

0.1 (8.26%)

18:01
11/20/17
11/20
18:01
11/20/17
18:01
Hot Stocks
Intermolecular partners with SITRI to develop MtM technologies »

Intermolecular, Inc and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CMCSA

Comcast

$35.83

-0.33 (-0.91%)

18:00
11/20/17
11/20
18:00
11/20/17
18:00
Initiation
Comcast initiated at Buckingham »

Comcast initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

17:59
11/20/17
11/20
17:59
11/20/17
17:59
Hot Stocks
Mellanox up nearly 6% after Starboard discloses a 9.8% stake in the company »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

PLNT

Planet Fitness

$30.15

0.07 (0.23%)

17:58
11/20/17
11/20
17:58
11/20/17
17:58
Initiation
Planet Fitness initiated at DA Davidson »

Planet Fitness initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$44.43

0.86 (1.97%)

17:57
11/20/17
11/20
17:57
11/20/17
17:57
Downgrade
Teradyne rating change at Deutsche Bank »

Teradyne downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CBS

CBS

$55.93

-0.81 (-1.43%)

17:56
11/20/17
11/20
17:56
11/20/17
17:56
Periodicals
CBS News suspends Charlie Rose following sexual harassment claims, AP says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$55.93

-0.81 (-1.43%)

17:55
11/20/17
11/20
17:55
11/20/17
17:55
Periodicals
Eight women accuse Charlie Rose of sexual harassment, Washington Post says »

Eight women have said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

, MRVL

Marvell

$21.59

1.3 (6.41%)

17:53
11/20/17
11/20
17:53
11/20/17
17:53
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox, may seek talks »

Peter A. Feld, a…

MLNX

Mellanox

$51.05

1 (2.00%)

MRVL

Marvell

$21.59

1.3 (6.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

CDXS

Codexis

17:46
11/20/17
11/20
17:46
11/20/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Telemark Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Hot Stocks
AT&T CEO says giving up control of CNN is a 'non-starter' »

Says plenty of solutions…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

BBY

Best Buy

$56.35

0.52 (0.93%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:43
11/20/17
11/20
17:43
11/20/17
17:43
Hot Stocks
AT&T CEO says DOJ suit 'defies logic' »

Says has offered…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RELY

Real Industry

$0.52

0.1643 (45.92%)

17:38
11/20/17
11/20
17:38
11/20/17
17:38
Hot Stocks
Real Industry, Real Alloy receive court approval of 'first day' motions »

Real Industry announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.